Insider Transactions Reported by 14 Insiders of Rubius Therapeutics, Inc.

Location: Foxboro, MA

Quick Takeaways

Rubius Therapeutics, Inc. has 14 insiders with reported activity on this page.
No net insider buy/sell flow is currently reported for the last year.
Recent transaction rows are not currently available.

What Changed

No meaningful buy/sell imbalance is currently visible in the one-year window.
Activity will update as new Forms 3/4/5 are filed.

Why This Matters

This page gives a plain-language issuer insider context before you inspect transaction-level evidence.
Use the filing links below to verify timestamps, codes, and ownership impacts directly from SEC forms.

Official SEC Source

Filed on Form 4

Issuer insider activity is sourced from SEC Forms 3, 4, and 5.

See Original Filing

Insider trading overview

Last 12 months

Insider buy and sell flow is broadly balanced over the last 12 months. No Buy or Sell transactions have been reported since 08 Apr 2025.

Buys

Shares: 0

Insiders: 0

Sells

Shares: 0

Insiders: 0

Net

Shares: 0

Insiders: 0

Window (months)	Buy $	Sell $	Net $
0-3	$0	$0	$0
3-6	$0	$0	$0
6-9	$0	$0	$0
9-12	$0	$0	$0

Rubius Therapeutics, Inc. executives and other stock owners filed with the SEC include:

Name	Relationship	Valuation	Report Date
David R. Epstein	Director	Mixed	12 May 2022
Ph.D. Noubar B. Afeyan	Director, 10%+ Owner	Mixed	12 May 2022
Francis M. Cuss	Director	Mixed	12 May 2022
Natalie C. Holles	Director	Mixed	12 May 2022
Jonathan Symonds	Director	Mixed	12 May 2022
Maiken Keson-Brookes	CLO & Corp. Secretary	Mixed	29 Jan 2022
Anne Prener	Director	Mixed	12 May 2022
Dannielle Appelhans	CEO and President	Mixed	24 Feb 2023
Laurence A. Turka	Chief Scientific Officer	Mixed	29 Jan 2023
Pablo J. Cagnoni	Director	Mixed	01 Feb 2023
Catherine A. Sohn	Director	Mixed	12 May 2022
Jose Carmona	Chief Financial Officer	Mixed	31 Jan 2022
Michael Rosenblatt	Director	Mixed	12 May 2022
Susanne Schaffert	Director	Mixed	29 Jul 2022

Top shareholders of Rubius Therapeutics, Inc. (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Holder	Source	Role / Reporting	Ownership %	Shares	Holdings Value	12M Net Δ	As of	Details
David R. Epstein	3/4/5	Director	— class O/S missing	499,762	—	—	12 May 2022	3/4/5
Maiken Keson-Brookes	3/4/5	CLO & Corp. Secretary	— mixed-class rows	183,593 mixed-class rows	—	—	29 Jan 2022	3/4/5
Jose Carmona	3/4/5	Chief Financial Officer	— mixed-class rows	178,250 mixed-class rows	—	—	31 Jan 2022	3/4/5
Pablo J. Cagnoni	3/4/5	Director	— mixed-class rows	141,082 mixed-class rows	—	—	01 Feb 2023	3/4/5
Susanne Schaffert	3/4/5	Director	— class O/S missing	50,000	—	—	29 Jul 2022	3/4/5
Laurence A. Turka	3/4/5	Chief Scientific Officer	— mixed-class rows	44,266 mixed-class rows	—	—	29 Jan 2023	3/4/5
Anne Prener	3/4/5	Director	— class O/S missing	25,000	—	—	12 May 2022	3/4/5
Catherine A. Sohn	3/4/5	Director	— class O/S missing	25,000	—	—	12 May 2022	3/4/5
Francis M. Cuss	3/4/5	Director	— class O/S missing	25,000	—	—	12 May 2022	3/4/5
Jonathan Symonds	3/4/5	Director	— class O/S missing	25,000	—	—	12 May 2022	3/4/5
Michael Rosenblatt	3/4/5	Director	— class O/S missing	25,000	—	—	12 May 2022	3/4/5
Natalie C. Holles	3/4/5	Director	— class O/S missing	25,000	—	—	12 May 2022	3/4/5
Ph.D. Noubar B. Afeyan	3/4/5	Director, 10%+ Owner	— class O/S missing	25,000	—	—	12 May 2022	3/4/5

Recent Insider Transactions by Companies or Individuals for Rubius Therapeutics, Inc.

Showing up to 300 most recent insider transactions from the last 12 months.

Insider	Symbol	Class	Transaction	%	Value $	* Price $	Shares	Shares Owned	Date	Ownership
No insider transactions were found in the last 12 months for this issuer.

* An asterisk sign (*) next to the price indicates that the price is likely invalid.